Daclizumab for the treatment of relapsing-remitting multiple sclerosis

摘要

Introduction: Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Over the last two decades, the number of therapeutic options for the treatment of relapsing remitting MS (RRMS) has been constantly growing, providing new treatment options to patients.